Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43854   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2007-001457-26
    Sponsor's Protocol Code Number:A6171016
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2007-11-12
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2007-001457-26
    A.3Full title of the trial
    A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP,
    PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE
    SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS
    WITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEE
    A.4.1Sponsor's protocol code numberA6171016
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPfizer Inc, 235 East 42nd Street, New York, NY 10017
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code SD-6010/ PHA-728669F
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 753491-31-5
    D.3.9.2Current sponsor codeSD-6010 / PHA-728669F
    D.3.9.3Other descriptive name(R)-3-[(2-Acetimidamidoethyl)sulfanyl]- 2-amino-2-methylpropanoic acid hemihydrochloride hemimaleate
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code SD-6010/ PHA-728669F
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 753491-31-5
    D.3.9.2Current sponsor codeSD-6010 / PHA-728669F
    D.3.9.3Other descriptive name(R)-3-[(2-Acetimidamidoethyl)sulfanyl]- 2-amino-2-methylpropanoic acid hemihydrochloride hemimaleate
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Osteoarthritis
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10023476
    E.1.2Term Knee osteoarthritis
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the disease modifying efficacy of SD-6010 50 mg and 200 mg QD compared to placebo in reducing the rate of progression of OA as assessed by radiographic JSN in the medial tibiofemoral compartment of the study knee of subjects with knee OA.
    E.2.2Secondary objectives of the trial
    1. To assess the safety and tolerability of SD-6010 50 mg and 200 mg QD administered long-term to subjects with knee OA;
    2. To assess the clinical benefit of SD-6010 50 mg and 200 mg QD in subjects with knee OA as measured by the clinical endpoints including, but not limited to, WOMAC, pain VAS (visual analog scale), changes in background pain therapy and use of rescue medication in the study knee.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Investigator Level Assessments for Inclusion
    1. Has provided written informed consent and is willing to comply with scheduled visits,treatment plan, radiographs, laboratory tests, and other trial procedures;
    2. Age ≥40 years with a BMI ≥25 and ≤40 kg/m2;
    3. In the past, has been diagnosed with knee OA and has had knee symptoms in the past year defined as:
    • Pain, aching or stiffness on most days of a month; and/or
    • Used a medication (other than potent opioids) for treatment of knee pain on
    most days of a month;
    4. If currently being treated for OA knee symptoms, has been on the same standard of care
    medication(s) and on a stable dosing regimen for at least 4 weeks preceding the first
    dose of study medication (stable defined as: Doses and frequency of administration
    remain unchanged);
    5. If female, is of non-childbearing potential, and 1 of the 2 categories below is satisfied:
    • Is ≥45 years of age and amenorrheic for at least 2 years, or
    • Has proof of a physician documented hysterectomy and/or bilateral oophorectomy;
    Note: Females not meeting the non-childbearing rules above or having undergone
    tubal ligation will be considered of childbearing potential for this study (refer to #6
    next).
    6. If a male, or a female of childbearing potential, has agreed that when sexually active, to use the protocol designated effective methods of contraception and abide by the time frames .

    Central Imaging Core Laboratory Criteria for Inclusion
    Subjects meeting the following Screen 1 inclusion criteria by radiography as assessed
    through the modified Lyon-schuss X-ray will be semi-qualified for Screen 2. Criteria 1-4
    below will be assessed by the independent Central Reader from data from the Central Imaging Core Laboratory for determining which subjects will be invited back for Screen 2.
    A “yes” answer to each criterion is needed to continue screening.
    1. KLG 2 or 3 with a medial tibiofemoral joint space width (JSW) ≥2 mm and more
    narrowed than the lateral JSW in the study knee;
    2. KLG <4 in the contralateral knee; unless the contralateral knee has KLG 4 changes and, in the opinion of the Investigator, the subject is unlikely to undergo arthroplasty within the next 2 years, the subject will be considered for eligibility. Conversely, if a subject is at risk of becoming incapacitated in the near future due to the KLG 4 changes such that activities of daily living are severely curtailed, the subject should not be considered for the trial.
    3. An anatomic axis angle (AAA) between 184° and 174°inclusive. If the study knee has KLG 3 changes and a medial JSW smaller than the lateral JSW with an AAA >184
    degrees, and if the other radiographic eligibility criteria are met, the subject will be
    considered for eligibility;
    4. No radiological findings such as, but not limited to avascular necrosis, fracture, infection, gout, Paget’s disease, osteopetrosis, osteochondritis, or other pathologies in the study knee.
    E.4Principal exclusion criteria
    1. Subjects with a history of:
    a. A diagnosis of any other rheumatic disease (eg, spondyloarthropathies, rheumatoid arthritis, systemic lupus erythematosus );
    b. Severe, uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological disease, or any other condition which would make the subject unsuitable for the study within 6 months preceding the Screen 1 visit;
    c. Uncontrolled diabetes, uncontrolled hyperglycemia, active foot wound infection, or a history of diabetic ulceration;
    d. Clinically significant infections (acute infection or those requiring hospitalization or requiring parenteral antimicrobial therapy) within 6 months preceding the Screen 1 visit;
    e. An active malignancy of any type or history of a malignancy (with the exception of subjects with malignancy surgically removed with no evidence of recurrence within the past 5 years, and with the exception of subjects with a history of treated nonmelanoma carcinoma);
    f. Any diseases or conditions involving the knees including, but not limited:
    -Crystalline disease (eg, gout, pseudogout; however, mild to moderate asymptomatic chondrocalcinosis is not an exclusion).
    -Endocrinopathies (eg, acromegaly)
    -Metabolic diseases (eg, ochronosis, hemochromatosis, Wilson’s disease, Gaucher’s disease)
    -Septic arthritis
    -Neuropathic disorders
    -Mechanical disorders (eg, hypermobility)
    -Avascular necrosis
    -Intra articular fracture
    -Microfractures, cartilage debridement, chondrocyte transplantation, mosaicplasty
    -Osteotomy, arthroplasty, osteophyte resection,
    -Paget’s disease, tumors, (eg, primary osteochondromatosis) or collagen gene mutations
    -Any injury/trauma of the knee resulting in anterior cruciate ligament (ACL)/posterior cruciate ligament (PCL) rupture or reconstruction and/or partial or total meniscectomy for traumatic meniscal tears; however, a partial or total meniscectomy for degenerative meniscal tears related to OA is not exclusionary.
    g. Significant trauma to the knees including significant injury to ligaments or menisci of the knee within 1 year preceding the Screen 1 visit;
    h. Alcoholism or drug abuse within 1 year preceding the Screen 1 visit;
    2. Subjects presenting with:
    a. A verified systolic blood pressure >150 mm Hg (if untreated for hypertension) or greater than 160 mm Hg (if treated for hypertension) and/or a diastolic blood pressure greater than 90 mm Hg;
    b. Any morbidities (eg, coronary heart disease, hypertension, dyspnea, diabetes, obesity, COPD, emphysema, depression, severe OA) that would curtail work related or leisure time physical activities (eg, walking, cooking, gardening, standing) such that these morbidities would contribute to increases in sedentary behaviors (eg, becoming chair or bed ridden, aka, “couch potato lifestyle”);
    c. Chronic potent opioid use for OA of the knees (propoxyphene, tramadol, codeine use is acceptable);
    d. Any condition possibly affecting oral drug absorption (eg, gastrectomy or clinically significant diabetic gastroenteropathy);
    e. Exacerbation of OA pain (eg, a flare) in either knee requiring a change in stable treatment within 4 weeks of the Screen 1 visit;
    f. Symptomatic OA of either hip by history or elicited on physical examination that may confound the interpretation of knee pain; Use of any investigational drug within 1 month preceding the Screen 1 visit;
    3. Pregnant or breastfeeding females;
    4. Anticipating a move out of the area of the clinic in the next 2 years;
    5. A subject anticipating a procedure (eg, gastric [bypass, banding, balloon], liposuction) for significant weight loss in the next 2 years or having undergone such a procedure in the last 3 months.
    E.5 End points
    E.5.1Primary end point(s)
    The progression rate of Joint space narrowing (JSN)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability, clinical benefit, analysis of IMP effect on OA progression
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA41
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of Trial in a Member State of the European Union is defined as the time at which it is deemed that sufficient subjects have been recruited and completed the study as stated in the regulatory application (ie, Clinical Trial Application [CTA]) and ethics application in the Member State. Poor recruitment (recruiting less than the anticipated number in the CTA) by a Member State is not a reason for premature termination but is considered a normal conclusion to the study in that Member State.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 421
    F.4.2.2In the whole clinical trial 1400
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-12-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-12-21
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2011-11-09
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 23 09:28:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA